Triad Healthcare Partners, a division of Triad Securities Corp., provides investment banking services to pharmaceutical and medical device companies on a global basis. The team has a particular focus in the specialty pharmaceutical sector.
Andrew Hirschberg and Mark Palmer work with specialty pharmaceutical clients to provide strategic advisory services related to all aspects of mergers, acquisitions and licensing activities on a global basis.
Andrew Hirschberg has been advising specialty pharmaceutical clients for 30 years and has completed over 100 transactions in multiple specialties (dermatology, gastroenterology, pediatrics, nephrology, etc.) with an aggregate value exceeding $5 billion.
Mark Palmer led business development for two specialty pharmaceutical companies (Braintree Laboratories, Inc. and Medicis Pharmaceutical Corp.) for the ten years prior to joining Triad Healthcare Partners. During that time, Mark led and completed transactions with an aggregate value of well over $1 billion. These transactions were primarily in dermatology, gastroenterology, orphan drugs and pediatrics.
Prior to forming Triad Healthcare Partners, Andrew and Mark worked together as investment bankers at another broker-dealer, where they advised clients on strategic transactions and completed multiple M&A and licensing deals.
Andrew and Mark work with companies throughout the development and commercialization timeline and assist with in/out-licensing and mergers and acquisitions to maximize value for the shareholders of client companies. They have vast experience in sourcing deals and representing clients in all aspects of deal making and negotiation in the global specialty pharmaceutical marketplace.